DF
Therapeutic Areas
FireCyte Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead IGFBPL1 Fusion Protein Program | Retinal disorders, primarily Glaucoma (including normotensive glaucoma) | Preclinical |
Leadership Team at FireCyte Therapeutics
BY
Bill Yelle
Co-Founder & CEO
JL
Jonathan Levenson
Chief Scientific Officer
JW
James W. Bryson
Head of Protein Engineering